NLS Pharma Pins Hopes On Ex-Obesity Drug For ADHD
Emerging Company Profile: NLS Pharma wants to develop novel treatments for ADHD, sleep disorders and cognitive impairments. Its big hope is mazindol CR, for which it has just announced promising Phase II data. The firm explains what is next.
You may also be interested in...
Sunovion is pressing ahead with plans for an FDA filing for its ADHD drug dasotraline in adult and children patients despite ongoing uncertainty over the drug's efficacy in the older grouping.
Health advocates hail the move but the EU and UK still insist a waiver is not the solution to boosting the availability of coronavirus vaccines.
The Russian Direct Investment Fund says it has 20 technology transfer and production agreements in place in 13 countries across the world.